Beth baber oen science summit
-
Upload
open-science-summit -
Category
Documents
-
view
588 -
download
0
description
Transcript of Beth baber oen science summit
By translating biomedical discoveries into an integrated, personalized treatment program
for children with cancer
By developing cancer-specific predictive tests to guide cancer therapy for each child
By bringing to the clinic new therapies that considers the unique molecular physiology
of the child and their cancer
Our Mission
is to meet this disease head on with better detection, diagnostic tools and kid friendly treatments that
bring hope to all those involved…
THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research
THE NICHOLAS CONOR INSTITUTE
Date of Dx: 7/19/05High-Risk Neuroblastoma
Combinatorial Chemotherapy, Surgery & Retinoic Acid Therapy
NED: 2 ½ years post treatment
Beth Anne Baber, Ph.D., Co-founder, President and CEO
Mother of Nicholas “Conor” Boddy
for Pediatric Cancer Research
“Not very many. Radiation was not an option … surgery was not an option. The only thing left washigh intensity chemotherapy.
Often children with his condition are given 10X the adult dose of chemotherapy that obviously leads to long-term side effects … You may not see these effects immediately, these long-term side- effects will occur as they grow into adulthood.”
-Beth Anne Baber, Conor’s MomBurrill Report Patient Perspective Podcast
July 2009
What kind of treatments option does a child like Conor have?
THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research
87,000 will die from the disease/yr worldwide
Survivors will suffer from the long-term, side-effects
Treatment choices are few and unpredictable
Rarity of individual childhood cancers discourages expensive commercial research and development
The facts are …1 out of 300 children will be diagnosed before age 20
Worldwide ~160,000 are diagnosed/yr.
The facts are … but we can make an impact
Unacceptable Market Reality
SITUTATION: If the projected revenue is <$800 M/yr, then NO new pediatric oncology drug development.
CURRENT STRATEGY: Piggyback onto adult products for the lack of pediatric targeted therapies AND often give the children 10X the adult dose.
PROBLEM: Small market and modest overlap between adult & childhood cancers.
CURRENT COST: ~ $500,000 to >$2,500,000 to treat each child
Leukemia (30%)
Brain & NS (22.3%)Lymphomas (8%)Neuroblastoma (7.3%)
Other cancers (32.4%)
Our advantage is the value we create
Develop
Validate
Apply
Baseline
6 months to 1 year
Acquire
Identify Technology& Industry Partner(s)
TNCI Value Creation
Time Horizon: 2-5 years
Translate
Research(Other Institutions)
Time
Clinic
Clinical application
TACTiC reduces R&D cost through sharing of resources.
TACTiC creates mini centers of excellence for childhood cancer in the biomedical industry.
TACTiCTM: Non-profit Strategy for Innovation
Obtain funding
•Government•Foundation•Philanthropy
Molecular Dx
CompanyIdentify industry partner
Commercialize or
Identify Partner
TACTiC is flexible and scalable
Establish on-site laboratory
Molecular Dx Company
The Accelerator of Cancer Treatments in Children
TACTiCTM
Prognosys BioSc & others TBA
AltheaDx CollabRx& others TBA
Industry Partners:
Genomics ProteomicsBio-
informatics CDxMDxCenters of Excellence for
Childhood Cancer:
The Nicholas Conor Institute
Academia
Children’s Oncology Group& Clinical Research Centers
International Consortiums
iChanneX & GenVault
Pediatric Cancer Outcome Exchange
TBA TBA
TACTiCTM: Non-profit Strategy for Innovation The advantages of TACTiCTM are many:
Quick start-up with built in capacity;
Provides a focused effort to translate key academic discoveries to the clinic;
Direct transfer of knowledge and expertise between industry and academia;
Economies of scale, sharing of infrastructure and capital equipment leads to lowers indirect cost;
Efficient use of research dollars appeals to funding organizations and donor investors;
Appeals to research institutes that license their discoveries for commercialization;
Allows for flexibility and easily scalable; and,
Aligns with our mission and differentiates The Nicholas Conor Institute from others.
The Nicholas Conor Institute’s Strategic & Patient Advocacy Partners
Children’s Rare Disease Network (CRDN, The Project)• Public awareness for children’s rare diseases, including Childhood Cancer
CureSearch for Children’s Cancer (National Childhood Cancer Foundation, NCCF)
• Support for Children’s Oncology Group• Support for TNCI personalize medicine initiatives• Public awareness for childhood cancer, the need for industry involvement,
and a personalize approach the treating childhood cancer
THE NICHOLAS CONOR INSTITUTEBoard of Directors
Beth Alton Chair of the Board of Directors Founder and CEO of Keene Solutions
Beth Anne Baber, Ph.D., MBA Co-founder and CEO
Martin Latterich, Ph.D. Co-founder and CSO
John Wooley, Ph.D. Assoc. Vice Chancellor of Research-UCSD
Geoff Wahl, Ph.D. Professor at the Salk Institute
Former President of the AACRTrustee of the AACR Foundation
Tony Hunter, Ph.D. Prof. & Director of the Salk Institute Cancer Center
Bud BromleyPresident and COO of Psynomics
Mort Freedman Former Chair of
Steele Children’s Research Center
Jeff WolfFounded and CEO of Wolf Management Consultants
Janet VohariwattFounder and CEO of iChanneX
David GeerdesAttorney at Law
THE NICHOLAS CONOR INSTITUTE for Pediatric Cancer Research
TheNicholasConorInstitute.org (TNCI.org)